Padsevonil

DRUG10 trials

Conditions

Adult Study ParticipantsDrug-Resistant EpilepsyDrug-resistant EpilepsyElderly Study ParticipantsEpilepsyFocal-Onset SeizuresHealthy Female ParticipantsHealthy Japanese Participants

Phase 1

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

CompletedNCT03695094

UCB Biopharma S.P.R.L.Epilepsy

Start: 2018-09-18End: 2019-05-30Updated: 2020-06-04

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

CompletedNCT04013191

UCB Biopharma S.P.R.L.Adult Study Participants, Elderly Study Participants

Start: 2019-07-09End: 2019-10-03Updated: 2021-06-30

A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either Ethanol or Cannabidiol

TerminatedNCT04039919

UCB Biopharma S.P.R.L.Healthy Participants

Start: 2019-07-17End: 2020-05-22Updated: 2021-06-18

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

CompletedNCT04075409

UCB Biopharma S.P.R.L.Healthy Japanese Participants

Start: 2019-09-30End: 2019-12-27Updated: 2021-07-08

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

TerminatedNCT04126343

UCB Biopharma S.P.R.L.Healthy Study Participants

Start: 2019-10-23End: 2020-05-22Updated: 2021-06-18

A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

TerminatedNCT04131517

UCB Biopharma SRLHealthy Female Participants

Start: 2019-10-23End: 2020-05-22Updated: 2021-06-24

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

TerminatedNCT04136444

UCB Biopharma S.P.R.L.Healthy Study Participants, Impaired Hepatic Function

Start: 2019-10-28End: 2020-05-22Updated: 2021-07-28

Phase 2

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

TerminatedNCT03370120

UCB Biopharma SRLDrug-Resistant Epilepsy, Focal-Onset Seizures

Start: 2018-08-27End: 2020-12-11Updated: 2021-12-29

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

CompletedNCT03373383

UCB Biopharma S.P.R.L.Drug-resistant Epilepsy, Focal-Onset Seizures

Start: 2018-02-12End: 2020-01-30Updated: 2023-12-19

Phase 3

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

TerminatedNCT03739840

UCB Biopharma SRLDrug-Resistant Epilepsy, Focal-Onset Seizures

Start: 2019-03-06End: 2020-09-28Updated: 2022-12-21

Related Papers

Overview of preclinical and clinical studies investigating pharmacokinetics and drug-drug interactions of padsevonil.

2024-07-09

Efficacy and safety of adjunctive padsevonil in adults with drug‐resistant focal epilepsy: Results from two double‐blind, randomized, placebo‐controlled trials